Jakob Dupont
Jakob Dupont is an Executive Partner in Private Equity at Sofinnova, bringing over two decades of oncology and therapeutic development experience. He has held senior R&D roles at Atara Biotherapeutics, Gossamer Bio, Genentech/Roche, and OncoMed Pharmaceuticals.
What Jakob can write
Sofinnova Investments writes $10M to $30M checks, larger than 97% of firms in the atlas.
Bars: how many firms report each check band. Highlighted: Sofinnova Investments.Career
- Genentech/Roche · Vice President and Global Head of Breast and Gynecologic Cancer Development
- OncoMed Pharmaceuticals, Inc. · Chief Medical Officer and Senior Vice President
- Gossamer Bio · Chief Medical Officer
- Atara Biotherapeutics · Global Head of Research & Development (R&D) and Executive Vice President
- Sofinnova · Executive Partner, Private EquityNow
Investments named in public bios
Focus
Education
Also at Sofinnova Investments
Partners like Jakob
At firms with a similar stage, sector and check size.
Alert me when Sofinnova Investments is active
One email when Jakob's firm raises a fund, adds a partner or shows new activity.
Send Mode VC your deck
Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckQuestions
Who is Jakob Dupont?
Jakob Dupont is an Executive Partner in Private Equity at Sofinnova, bringing over two decades of oncology and therapeutic development experience. He has held senior R&D roles at Atara Biotherapeutics, Gossamer Bio, Genentech/Roche, and OncoMed Pharmaceuticals.
How much does Jakob Dupont invest?
Jakob Dupont invests through Sofinnova Investments, which writes checks of $10M to $30M at series a, series b.
How do I pitch Jakob Dupont?
Email [email protected], the firm's inbox for founders, and name Jakob in the subject. A warm intro from a founder Sofinnova Investments backed works better.
What did Jakob Dupont do before Sofinnova Investments?
Vice President and Global Head of Breast and Gynecologic Cancer Development at Genentech/Roche; Chief Medical Officer and Senior Vice President at OncoMed Pharmaceuticals, Inc.; Chief Medical Officer at Gossamer Bio; Global Head of Research & Development (R&D) and Executive Vice President at Atara Biotherapeutics.
Last updated 2026-10-15. Is this you? Ask for a correction.